• Z-YVAD-FMK: Translating Pyroptosis Mechanisms

  2026-08-26

  A mechanistic and translational guide to using Z-YVAD-FMK as a caspase-1 inhibitor in pyroptosis research, inflammasome activation studies, apoptosis assays, and cancer research.

• Cyclic di-GMP: Biofilm and STING Workflows

  2026-08-26

  Cyclic di-GMP connects two practical research areas: biofilm persistence and STING-driven immune modulation. This workflow guide translates its antitoxin activity into bacterial assays while outlining controlled, exploratory use in cancer immunotherapy studies.

• Low-Molecular-Weight Inhibitors of Complement

  2026-08-25

  The reference review explains how dysregulated alternative complement activity drives diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and age-related macular degeneration. Its central contribution is a mechanistic and translational framework for developing selective, orally available low-molecular-weight inhibitors of factor B and factor D, while clarifying the assays and disease models needed to evaluate them.

• MDM1, p53, and Chemoradiotherapy Sensitivity in CRC

  2026-08-25

  A 2025 Cancer Biology & Medicine study identifies MDM1 as a regulator of TP53 expression and chemoradiotherapy response in colorectal cancer. Its genetic, transcriptomic, cellular, and xenograft evidence supports MDM1 as a candidate predictive biomarker and points to apoptosis-focused combination strategies for tumors with low MDM1 expression.

• Z-WEHD-FMK in Caspase-1 Pyroptosis Studies

  2026-08-24

  Z-WEHD-FMK is a cell-permeable, irreversible inhibitor for testing inflammatory caspase activity across pyroptosis, infection, and tumor-cell models. This workflow separates validated Chlamydia applications from exploratory NSCLC experiments inspired by the HOXC8–caspase-1 study, helping researchers choose controls and interpret incomplete pathway blockade.

• Bacitracin B1670: Practical Protocol and QC Guide

  2026-08-24

  Bacitracin B1670 is a peptide antibiotic reagent for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis. This guide covers solvent selection, assay setup, controls, and product-specific QC boundaries; it is not intended for diagnostic, clinical, therapeutic, or medical use.

• Z-YVAD-FMK: Reading Caspase-1 Biology

  2026-08-23

  Z-YVAD-FMK is a cell-permeable, irreversible caspase-1 inhibitor for dissecting inflammasome signaling, pyroptosis, and related cell-death phenotypes. This article connects its use to gasdermin-resolved assay design and explains why inhibition should be paired with pathway-specific readouts.

• Z-VAD-FMK: Practical Apoptosis Workflow

  2026-08-22

  Learn how Z-VAD-FMK (Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone), SKU A1902, can clarify caspase-dependent viability and apoptosis results in THP-1, Jurkat, and other cell models. This scenario-based guide covers experimental controls, DMSO handling, protocol optimization, interpretation, and practical product selection.

• Exo1 for Exocytosis and Membrane Trafficking

  2026-08-22

  Exo1 enables acute, mechanistically distinct inhibition of ER-to-Golgi traffic for exocytosis assays, secretory-pathway mapping, and ARF1-focused experiments. This guide connects that bench workflow to tumor extracellular-vesicle research while clearly separating validated product behavior from exploratory applications.

• Saracatinib (AZD0530) Experimental Workflow

  2026-08-21

  Build a controlled Saracatinib workflow for Src/Abl pathway interrogation, cancer cell proliferation inhibition, and migration studies. The guide also explains how findings on Reelin–SFK signaling can inform assay design without overstating cross-domain evidence.

• Lipidated Nanophotosensitizer Blocks Tumor Spread

  2026-08-20

  The reference study introduces a palmitic-acid-displayed nanoparticle that both traces tumor extracellular vesicles and delivers photodynamic damage to intracellular and vesicular compartments. Its dual-distribution strategy suppresses primary tumors while disrupting TEV-mediated communication and metastasis in multiple mouse models, suggesting a way to address tumor growth and dissemination within one spatially coordinated treatment.

• Neuroligin 1, D2-MSNs, and Repetitive Behavior

  2026-08-20

  The reference study identifies striatal D2 receptor-expressing medium spiny neurons as a cell-type-specific circuit node linking Neuroligin 1 loss to excessive self-grooming and digging. By combining behavioral analysis, neuronal activity manipulation, single-nucleus RNA sequencing, and protein validation, it implicates abnormal PKC signaling and distinct activity patterns in restricted and repetitive behavior.

• Neurospora crassa Auxin Biosynthesis via the IPA Pathway

  2026-08-19

  Sardar and Kempken characterized an indole-3-pyruvic acid pathway for indole-3-acetic acid biosynthesis in Neurospora crassa by combining computational gene identification, metabolite analysis, and targeted mutants. Their results connect candidate fungal genes to IAA production and conidiation, providing a useful framework for fungal auxin biology and comparative plant hormone research.

• RSL3: Glutathione Peroxidase 4 Inhibitor Guide

  2026-08-19

  A scenario-based laboratory guide to using (1S,3R)-RSL3 glutathione peroxidase 4 inhibitor (SKU B6095) in ferroptosis, viability, and cytotoxicity workflows. It connects formulation, controls, assay interpretation, and supplier selection with practical evidence and cited mechanistic context.

• Oteseconazole (VT-1161): From CYP51 to Translation

  2026-08-18

  Oteseconazole (VT-1161) illustrates how selective fungal CYP51 inhibition can connect molecular design, Candida susceptibility testing, resistance-aware development, and clinical strategy. This thought-leadership perspective outlines how translational researchers can use the compound responsibly while distinguishing assay potency from therapeutic performance.

3575 records 1/239 page Next 12345 下5页 Last page